NO321202B1 - Anvendelse av material avledet fra Mycobacterium vaccae til fremstilling av et medikament for nedregulering av Th2 aktiviteten til immunsystemet - Google Patents
Anvendelse av material avledet fra Mycobacterium vaccae til fremstilling av et medikament for nedregulering av Th2 aktiviteten til immunsystemet Download PDFInfo
- Publication number
- NO321202B1 NO321202B1 NO19992957A NO992957A NO321202B1 NO 321202 B1 NO321202 B1 NO 321202B1 NO 19992957 A NO19992957 A NO 19992957A NO 992957 A NO992957 A NO 992957A NO 321202 B1 NO321202 B1 NO 321202B1
- Authority
- NO
- Norway
- Prior art keywords
- vaccae
- ova
- activity
- mice
- treatment
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims description 65
- 241000187644 Mycobacterium vaccae Species 0.000 title claims description 53
- 239000000463 material Substances 0.000 title claims description 15
- 210000000987 immune system Anatomy 0.000 title claims description 12
- 239000003814 drug Substances 0.000 title claims description 10
- 230000003828 downregulation Effects 0.000 title description 8
- 229940079593 drug Drugs 0.000 title description 6
- 238000011282 treatment Methods 0.000 claims description 46
- 239000000427 antigen Substances 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 20
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 239000013566 allergen Substances 0.000 claims description 9
- 230000003827 upregulation Effects 0.000 claims description 9
- 230000004957 immunoregulator effect Effects 0.000 claims description 8
- 230000000890 antigenic effect Effects 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 206010056557 Gulf war syndrome Diseases 0.000 claims description 6
- 201000010076 persian gulf syndrome Diseases 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 208000002430 Multiple chemical sensitivity Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 230000004044 response Effects 0.000 description 42
- 102000004127 Cytokines Human genes 0.000 description 35
- 108090000695 Cytokines Proteins 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 33
- 239000011780 sodium chloride Substances 0.000 description 31
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 22
- 210000004989 spleen cell Anatomy 0.000 description 22
- 108010002350 Interleukin-2 Proteins 0.000 description 21
- 102000000588 Interleukin-2 Human genes 0.000 description 21
- 230000003053 immunization Effects 0.000 description 21
- 238000002649 immunization Methods 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- 108010002616 Interleukin-5 Proteins 0.000 description 17
- 102000000743 Interleukin-5 Human genes 0.000 description 17
- 108010058846 Ovalbumin Proteins 0.000 description 17
- 229940092253 ovalbumin Drugs 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000002255 vaccination Methods 0.000 description 14
- 230000009885 systemic effect Effects 0.000 description 13
- 238000011725 BALB/c mouse Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 229960000890 hydrocortisone Drugs 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229960002847 prasterone Drugs 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 201000008827 tuberculosis Diseases 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000004073 interleukin-2 production Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 206010003645 Atopy Diseases 0.000 description 4
- 241001274613 Corvus frugilegus Species 0.000 description 4
- 208000004262 Food Hypersensitivity Diseases 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 201000005505 Measles Diseases 0.000 description 4
- 210000004241 Th2 cell Anatomy 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 235000020932 food allergy Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000005702 Pertussis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229960004544 cortisone Drugs 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960001005 tuberculin Drugs 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003710 calcium ionophore Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001886 cortisols Chemical class 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 230000017307 interleukin-4 production Effects 0.000 description 2
- 230000022023 interleukin-5 production Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000018555 lymphatic system disease Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 101100152731 Arabidopsis thaliana TH2 gene Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 241000220259 Raphanus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960004784 allergens Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 150000001642 boronic acid derivatives Chemical group 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- -1 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229960005097 diphtheria vaccines Drugs 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960004465 metyrapone Drugs 0.000 description 1
- FJLBFSROUSIWMA-UHFFFAOYSA-N metyrapone Chemical compound C=1C=CN=CC=1C(C)(C)C(=O)C1=CC=CN=C1 FJLBFSROUSIWMA-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000009670 mycobacterial growth Effects 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002766 tetanus vaccines Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9626215.9A GB9626215D0 (en) | 1996-12-18 | 1996-12-18 | A therapeutic agent and its use |
| GBGB9626859.4A GB9626859D0 (en) | 1996-12-24 | 1996-12-24 | Medical treatment |
| PCT/GB1997/003460 WO1998026790A1 (en) | 1996-12-18 | 1997-12-17 | Mycobacterium vaccae for down-regulation of the th2 activity of the immune system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO992957D0 NO992957D0 (no) | 1999-06-17 |
| NO992957L NO992957L (no) | 1999-08-10 |
| NO321202B1 true NO321202B1 (no) | 2006-04-03 |
Family
ID=26310662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19992957A NO321202B1 (no) | 1996-12-18 | 1999-06-17 | Anvendelse av material avledet fra Mycobacterium vaccae til fremstilling av et medikament for nedregulering av Th2 aktiviteten til immunsystemet |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0951289B1 (de) |
| JP (1) | JP4358306B2 (de) |
| KR (1) | KR100533818B1 (de) |
| CN (1) | CN1129453C (de) |
| AP (1) | AP1044A (de) |
| AT (1) | ATE307600T1 (de) |
| AU (1) | AU730548B2 (de) |
| BR (1) | BR9713959A (de) |
| CA (1) | CA2273848C (de) |
| DE (1) | DE69734461T2 (de) |
| DK (1) | DK0951289T3 (de) |
| ES (1) | ES2251744T3 (de) |
| FI (1) | FI120136B (de) |
| HK (1) | HK1021316A1 (de) |
| NO (1) | NO321202B1 (de) |
| NZ (1) | NZ336147A (de) |
| RU (1) | RU2197989C2 (de) |
| WO (1) | WO1998026790A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6361776B1 (en) * | 1999-12-06 | 2002-03-26 | Genesis Research & Development Corp. Ltd. | Compounds isolated from M. vaccae and their use in modulation of immune responses |
| JP2003535903A (ja) * | 2000-06-19 | 2003-12-02 | ミューコプロテック・プロプライエタリー・リミテッド | プロバイオティックを用いた、粘膜表面での細菌またはウイルス感染の免疫療法または治療、およびそのための組成物 |
| AUPR101600A0 (en) * | 2000-10-25 | 2000-11-16 | Atheromastat Pty Ltd | Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| WO2002066055A1 (en) | 2001-02-20 | 2002-08-29 | Maruho Co., Ltd. | NOVEL MEDICINAL USE OF α ANTIGEN OR α ANTIGEN GENE |
| EP3319635B1 (de) * | 2015-06-24 | 2021-04-21 | Immodulon Therapeutics Limited | Checkpoint-inhibitor und ganzzelliges mycobakterium zur verwendung in der krebstherapie |
| US11077179B2 (en) | 2017-08-10 | 2021-08-03 | Epicgenetics, Inc. | Method for treating fibromyalgia and chronic fatigue syndrome |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71683A0 (en) * | 1984-04-27 | 1984-09-30 | Yeda Res & Dev | Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria |
| GB9219425D0 (en) * | 1992-09-14 | 1992-10-28 | Univ London | Therapeutic agent and its use |
| GB8919321D0 (en) * | 1989-08-25 | 1989-10-11 | Univ London | Treatment of chronic inflammatory conditions |
| DE69126668T2 (de) * | 1990-11-08 | 1997-10-23 | Univ London | Mycobacterium als adjuvans für antigene |
| GB9203814D0 (en) * | 1992-02-21 | 1992-04-08 | Univ London | Treatment of long term auto-immune conditions |
| GB9406301D0 (en) * | 1994-03-30 | 1994-05-25 | Univ London | Immunotherapeutic agent and its use |
| AUPM864894A0 (en) * | 1994-10-07 | 1994-11-03 | Borody, Thomas Julius | Treatment of bowel-dependent neurological disorders |
-
1997
- 1997-12-17 AU AU77355/98A patent/AU730548B2/en not_active Ceased
- 1997-12-17 AT AT97949067T patent/ATE307600T1/de active
- 1997-12-17 RU RU99116029/14A patent/RU2197989C2/ru not_active IP Right Cessation
- 1997-12-17 JP JP52745698A patent/JP4358306B2/ja not_active Expired - Fee Related
- 1997-12-17 KR KR10-1999-7005412A patent/KR100533818B1/ko not_active IP Right Cessation
- 1997-12-17 CN CN97181765A patent/CN1129453C/zh not_active Expired - Fee Related
- 1997-12-17 CA CA002273848A patent/CA2273848C/en not_active Expired - Fee Related
- 1997-12-17 EP EP97949067A patent/EP0951289B1/de not_active Expired - Lifetime
- 1997-12-17 NZ NZ336147A patent/NZ336147A/en not_active IP Right Cessation
- 1997-12-17 ES ES97949067T patent/ES2251744T3/es not_active Expired - Lifetime
- 1997-12-17 DK DK97949067T patent/DK0951289T3/da active
- 1997-12-17 AP APAP/P/1999/001553A patent/AP1044A/en active
- 1997-12-17 BR BR9713959-9A patent/BR9713959A/pt not_active IP Right Cessation
- 1997-12-17 WO PCT/GB1997/003460 patent/WO1998026790A1/en active IP Right Grant
- 1997-12-17 DE DE69734461T patent/DE69734461T2/de not_active Expired - Lifetime
-
1999
- 1999-06-17 FI FI991384A patent/FI120136B/fi not_active IP Right Cessation
- 1999-06-17 NO NO19992957A patent/NO321202B1/no not_active IP Right Cessation
- 1999-12-24 HK HK99106112A patent/HK1021316A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AP1044A (en) | 2002-02-18 |
| CN1129453C (zh) | 2003-12-03 |
| KR100533818B1 (ko) | 2005-12-07 |
| JP4358306B2 (ja) | 2009-11-04 |
| ATE307600T1 (de) | 2005-11-15 |
| JP2001506256A (ja) | 2001-05-15 |
| WO1998026790A1 (en) | 1998-06-25 |
| RU2197989C2 (ru) | 2003-02-10 |
| FI991384A0 (fi) | 1999-06-17 |
| NO992957L (no) | 1999-08-10 |
| KR20000069518A (ko) | 2000-11-25 |
| FI120136B (fi) | 2009-07-15 |
| CA2273848A1 (en) | 1998-06-25 |
| NZ336147A (en) | 2001-03-30 |
| EP0951289B1 (de) | 2005-10-26 |
| CA2273848C (en) | 2008-02-19 |
| AU730548B2 (en) | 2001-03-08 |
| DK0951289T3 (da) | 2006-03-13 |
| AU7735598A (en) | 1998-07-15 |
| FI991384A (fi) | 1999-06-17 |
| EP0951289A1 (de) | 1999-10-27 |
| HK1021316A1 (en) | 2000-06-09 |
| ES2251744T3 (es) | 2006-05-01 |
| CN1246056A (zh) | 2000-03-01 |
| BR9713959A (pt) | 2000-04-11 |
| NO992957D0 (no) | 1999-06-17 |
| DE69734461T2 (de) | 2006-07-06 |
| AP9901553A0 (en) | 1999-06-30 |
| DE69734461D1 (de) | 2005-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Malling et al. | Local immunotherapy | |
| Aldwell et al. | Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis | |
| Wallace et al. | A role for intestinal T lymphocytes in bronchus mucosal immunity. | |
| JP5101795B2 (ja) | 免疫モジュレーターとしての全細菌細胞 | |
| Agrawal et al. | Flt3 ligand: a novel cytokine prevents allergic asthma in a mouse model | |
| EP1684803B1 (de) | Immunmodulator mit ganzzell-tsukamurella bakterien | |
| CA2273848C (en) | Mycobacterium vaccae for down-regulation of the th2 activity of the immune system | |
| Turner et al. | In vitro investigations in asthmatic children undergoing hyposensitization with tyrosine‐adsorbed Dermatophagoides pteronyssinus antigen | |
| US6878377B2 (en) | Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system | |
| AU779163B2 (en) | Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae | |
| EP1962898A1 (de) | Verwendung ganzzelliger actinomyceten zur behandlung von belastungsinduzierter lungenblutung | |
| CN104411326A (zh) | 抗哮喘的mtb-c疫苗 | |
| MXPA99005553A (en) | Mycobacterium vaccae | |
| HU226255B1 (en) | Mycobacterium vaccae for down-regulation of the th2 activity of the immune system | |
| Moore et al. | Effect of antimacrophage serum on dermal tuberculin sensitivity and allergic pulmonary granuloma formation in rabbits | |
| Costello et al. | Behavior of attenuated mycobacteria in organs of neonatal and adult mice | |
| US20040247622A1 (en) | Methods and compounds for the treatment of immunologically-mediated diseases using Mycobacterium vaccae | |
| KR20010113691A (ko) | Ｍ．배키를 이용한 만성 바이러스 감염의 치료 | |
| WO2002074330A2 (en) | Mycobacterrial estracts for treating autoimmune diseases | |
| Koostra et al. | Gonococcal ribosomes as skin test antigens. I. Preliminary tests of sensitivity and specificity. | |
| WO2003006035A1 (en) | Anti-emetic compositions comprising mycobacterial material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |